TB-500 Peptide

## What it is TB-500 is a synthetic peptide marketed as a research analog of Thymosin Beta-4 (TB4), an endogenous 43-amino-acid actin-sequestering protein expressed in nearly every human cell. Commercial TB-500 is typically a 17-amino-acid active fragment of TB4 rather than the full-length protein, and is sometimes acetylated. The compound was originally synthesized as a research tool to study actin dynamics and wound repair, and has no completed FDA review or drug-development program in humans. It is not approved as a drug in any major market. Veterinary use is the most documented real-world application: equine sports medicine has used TB-500 for soft-tissue injury since the 2000s, and several high-profile racehorse positives drove the WADA Prohibited List addition under category S2 in 2018. Human use is experimental and predominantly confined to athletes pursuing recovery off-label, longevity-focused users in research-peptide circles, and weekend warriors treating chronic tendon or ligament injury. ## Mechanism of action TB4 sequesters monomeric G-actin, which regulates the assembly of actin filaments during cell migration, tissue repair, and angiogenesis. The active fragment used in TB-500 retains the actin-binding motif and modulates cell migration and angiogenic signaling. Preclinical work documents upregulation of vascular endothelial growth factor (VEGF), increased myosin transcription, and enhanced endothelial differentiation and stem-cell trafficking to injury sites. Plasma half-life of full-length TB4 in rodent and equine models is roughly 2 hours, but local tissue effects appear to outlast plasma exposure. PEGylated research variants extend half-life substantially. The pharmacokinetics of the commercial 17-amino-acid fragment in humans have not been formally characterized in published trials. ## Evidence base Human trial evidence is essentially absent. The compound has not progressed past phase 1 in any indication, and no completed phase 2 or phase 3 RCTs exist for TB-500 specifically as of 2026. The published literature is dominated by preclinical work on full-length TB4. In rodent skin-wound models, exogenous TB4 accelerated re-epithelialization by 1 to 2 days versus saline, with corresponding histologic improvements in granulation tissue. Cardiac infarct studies in mice reported reduced scar volume and improved ejection fraction at 4 to 8 weeks post-occlusion when TB4 was administered shortly after the injury. Equine tendon studies have shown faster return-to-work timelines in animals receiving TB-500 versus rest alone, though most of these are vendor-funded or open-label. A Goldstein 2012 review summarized the angiogenic and cytoprotective signaling, and Crockford 2010 covered the equine soft-tissue evidence. Human data on the commercial fragment is restricted to anecdotal forum reports of subjective recovery acceleration in tendinopathy and post-surgical contexts. These reports are not controlled, are subject to substantial selection bias, and should be treated as hypothesis-generating rather than evidence of benefit. Long-term human safety is unestablished. Theoretical concerns include accelerated growth of occult malignancy via angiogenic and cell-migration effects, though no clinical signal has been documented because no clinical surveillance program exists. ## Dosage and administration Anecdotal protocols typically run a 4 to 6 week loading phase at 2 to 5 mg twice weekly subcutaneously, followed by weekly maintenance at 2 to 5 mg. Some users front-load with 5 mg twice weekly for 2 to 3 weeks then taper. There is no controlled human data to support any specific cycling pattern. A typical 5 mg vial reconstituted with 2.5 mL bacteriostatic water gives 2 mg/mL. A 2 mg dose equals 100 units on a U100 insulin syringe. Common injection sites are abdomen, thigh, and deltoid. Some protocols use intramuscular delivery near the injury site, on the rationale of local tissue exposure, though there is no controlled data showing this is superior to subcutaneous dosing. Reference the existing typicalDoseMg of 2.5 and the 2x weekly dosing frequency as starting points. Individual response and tolerance vary widely. ## Side effects and safety Reported anecdotal adverse effects include injection-site irritation, mild fatigue and lethargy in the first 1 to 2 weeks of dosing (sometimes attributed to systemic angiogenic activity), and rare transient headache. Acute tolerability appears generally mild in the absence of formal trials, but no controlled human safety data exists. Contraindications on theoretical grounds include pregnancy, lactation, and active malignancy (the angiogenic and migratory effects could theoretically support tumor growth, although no clinical signal has been established). The compound is frequently co-administered with BPC-157 in anecdotal recovery protocols; there is no controlled interaction data on the pairing. Athletes subject to anti-doping testing should know that WADA-accredited labs can detect TB-500 metabolites and several athlete sanctions have been published since the 2018 listing. ## Practical notes Lyophilized vials should be stored refrigerated. Once reconstituted with bacteriostatic water, stability is typically 4 to 6 weeks refrigerated, though research-peptide quality control varies considerably. Color should be clear; cloudiness, particles, or discoloration warrant discarding the vial. Users report subjective improvement in chronic tendon pain or post-injury recovery within 2 to 4 weeks, with most of the perceived benefit accumulating over 4 to 8 weeks. Given the absence of controlled human evidence, the honest framing is that any individual outcome is not distinguishable from regression to the mean, placebo, or the natural healing course. Pair with conservative loading, eccentric tendon work, and adequate protein intake; do not let TB-500 substitute for the rehabilitation work that has actual evidence behind it.